BNP PARIBAS ASSET MANAGEMENT Holding S.A. Has $17.20 Million Stock Position in Bicycle Therapeutics plc (NASDAQ:BCYC)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. lowered its stake in Bicycle Therapeutics plc (NASDAQ:BCYC) by 14.4% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 759,887 shares of the company’s stock after selling 128,194 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in Bicycle Therapeutics were worth $17,196,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Avoro Capital Advisors LLC acquired a new position in Bicycle Therapeutics in the 2nd quarter worth $14,168,000. Perceptive Advisors LLC bought a new stake in shares of Bicycle Therapeutics in the second quarter valued at about $11,577,000. Principal Financial Group Inc. acquired a new position in shares of Bicycle Therapeutics during the third quarter worth about $10,028,000. Armistice Capital LLC boosted its position in shares of Bicycle Therapeutics by 17.9% during the second quarter. Armistice Capital LLC now owns 1,972,000 shares of the company’s stock worth $39,913,000 after buying an additional 300,000 shares during the period. Finally, First Light Asset Management LLC grew its holdings in shares of Bicycle Therapeutics by 16.1% during the second quarter. First Light Asset Management LLC now owns 1,384,768 shares of the company’s stock worth $28,028,000 after buying an additional 191,717 shares in the last quarter. Institutional investors and hedge funds own 86.15% of the company’s stock.

Insider Transactions at Bicycle Therapeutics

In other Bicycle Therapeutics news, CEO Kevin Lee sold 3,212 shares of the stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $22.26, for a total transaction of $71,499.12. Following the transaction, the chief executive officer now owns 380,864 shares in the company, valued at $8,478,032.64. This trade represents a 0.84 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Travis Alvin Thompson sold 6,256 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $25.11, for a total transaction of $157,088.16. Following the completion of the sale, the chief accounting officer now directly owns 19,241 shares of the company’s stock, valued at approximately $483,141.51. The trade was a 24.54 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 10,840 shares of company stock worth $259,128. 8.50% of the stock is owned by insiders.

Bicycle Therapeutics Stock Up 1.4 %

Shares of NASDAQ BCYC opened at $20.54 on Friday. Bicycle Therapeutics plc has a twelve month low of $13.31 and a twelve month high of $28.67. The company has a market cap of $976.68 million, a PE ratio of -6.24 and a beta of 0.89. The business’s 50 day moving average price is $23.97 and its two-hundred day moving average price is $23.04.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.04. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The business had revenue of $2.68 million for the quarter, compared to analysts’ expectations of $6.82 million. During the same quarter in the prior year, the business earned ($1.26) EPS. The firm’s revenue for the quarter was down 50.0% on a year-over-year basis. As a group, research analysts anticipate that Bicycle Therapeutics plc will post -3.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on BCYC shares. Oppenheimer reaffirmed an “outperform” rating and set a $48.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, August 7th. JMP Securities reaffirmed a “market outperform” rating and issued a $32.00 target price on shares of Bicycle Therapeutics in a research report on Monday, September 16th. Needham & Company LLC reissued a “buy” rating and set a $38.00 price target on shares of Bicycle Therapeutics in a research report on Thursday, October 31st. Cantor Fitzgerald restated an “overweight” rating on shares of Bicycle Therapeutics in a report on Monday, September 9th. Finally, B. Riley lowered Bicycle Therapeutics from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $33.00 to $28.00 in a report on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.13.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.